217 related articles for article (PubMed ID: 32417188)
1. Targeting the spliceosome machinery: A new therapeutic axis in cancer?
Eymin B
Biochem Pharmacol; 2021 Jul; 189():114039. PubMed ID: 32417188
[TBL] [Abstract][Full Text] [Related]
2. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
Urbanski LM; Leclair N; Anczuków O
Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
[TBL] [Abstract][Full Text] [Related]
3. Disruption of exon-bridging interactions between the minor and major spliceosomes results in alternative splicing around minor introns.
Olthof AM; White AK; Mieruszynski S; Doggett K; Lee MF; Chakroun A; Abdel Aleem AK; Rousseau J; Magnani C; Roifman CM; Campeau PM; Heath JK; Kanadia RN
Nucleic Acids Res; 2021 Apr; 49(6):3524-3545. PubMed ID: 33660780
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and Regulation of Alternative Pre-mRNA Splicing.
Lee Y; Rio DC
Annu Rev Biochem; 2015; 84():291-323. PubMed ID: 25784052
[TBL] [Abstract][Full Text] [Related]
5. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
[TBL] [Abstract][Full Text] [Related]
6. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.
Seiler M; Yoshimi A; Darman R; Chan B; Keaney G; Thomas M; Agrawal AA; Caleb B; Csibi A; Sean E; Fekkes P; Karr C; Klimek V; Lai G; Lee L; Kumar P; Lee SC; Liu X; Mackenzie C; Meeske C; Mizui Y; Padron E; Park E; Pazolli E; Peng S; Prajapati S; Taylor J; Teng T; Wang J; Warmuth M; Yao H; Yu L; Zhu P; Abdel-Wahab O; Smith PG; Buonamici S
Nat Med; 2018 May; 24(4):497-504. PubMed ID: 29457796
[TBL] [Abstract][Full Text] [Related]
7. Targeting splicing factors for cancer therapy.
Bashari A; Siegfried Z; Karni R
RNA; 2023 Apr; 29(4):506-515. PubMed ID: 36697261
[TBL] [Abstract][Full Text] [Related]
8. Emerging roles of spliceosome in cancer and immunity.
Yang H; Beutler B; Zhang D
Protein Cell; 2022 Aug; 13(8):559-579. PubMed ID: 34196950
[TBL] [Abstract][Full Text] [Related]
9. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
10. The spliceosome as target for anticancer treatment.
van Alphen RJ; Wiemer EA; Burger H; Eskens FA
Br J Cancer; 2009 Jan; 100(2):228-32. PubMed ID: 19034274
[TBL] [Abstract][Full Text] [Related]
11. Identification of phenothiazine derivatives as UHM-binding inhibitors of early spliceosome assembly.
Jagtap PKA; Kubelka T; Soni K; Will CL; Garg D; Sippel C; Kapp TG; Potukuchi HK; Schorpp K; Hadian K; Kessler H; Lührmann R; Hausch F; Bach T; Sattler M
Nat Commun; 2020 Nov; 11(1):5621. PubMed ID: 33159082
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.
Huang HH; Ferguson ID; Thornton AM; Bastola P; Lam C; Lin YT; Choudhry P; Mariano MC; Marcoulis MD; Teo CF; Malato J; Phojanakong PJ; Martin TG; Wolf JL; Wong SW; Shah N; Hann B; Brooks AN; Wiita AP
Nat Commun; 2020 Apr; 11(1):1931. PubMed ID: 32321912
[TBL] [Abstract][Full Text] [Related]
13. The spliceosome as a target of novel antitumour drugs.
Bonnal S; Vigevani L; Valcárcel J
Nat Rev Drug Discov; 2012 Nov; 11(11):847-59. PubMed ID: 23123942
[TBL] [Abstract][Full Text] [Related]
14. The architecture of pre-mRNAs affects mechanisms of splice-site pairing.
Fox-Walsh KL; Dou Y; Lam BJ; Hung SP; Baldi PF; Hertel KJ
Proc Natl Acad Sci U S A; 2005 Nov; 102(45):16176-81. PubMed ID: 16260721
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping.
Wu G; Fan L; Edmonson MN; Shaw T; Boggs K; Easton J; Rusch MC; Webb TR; Zhang J; Potter PM
RNA; 2018 Aug; 24(8):1056-1066. PubMed ID: 29844105
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of RNA Splicing in Cancer.
Bonner EA; Lee SC
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510283
[TBL] [Abstract][Full Text] [Related]
17. Splicing diversity revealed by reduced spliceosomes in C. merolae and other organisms.
Hudson AJ; Stark MR; Fast NM; Russell AG; Rader SD
RNA Biol; 2015; 12(11):1-8. PubMed ID: 26400738
[TBL] [Abstract][Full Text] [Related]
18. Dysferlin rescue by spliceosome-mediated pre-mRNA trans-splicing targeting introns harbouring weakly defined 3' splice sites.
Philippi S; Lorain S; Beley C; Peccate C; Précigout G; Spuler S; Garcia L
Hum Mol Genet; 2015 Jul; 24(14):4049-60. PubMed ID: 25904108
[TBL] [Abstract][Full Text] [Related]
19. Messenger RNA reprogramming by spliceosome-mediated RNA trans-splicing.
Garcia-Blanco MA
J Clin Invest; 2003 Aug; 112(4):474-80. PubMed ID: 12925685
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.
Lin JC
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
